Company / Return on Equity (ROE)
Opus Genetics, Inc. Return on Equity (ROE) History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-855.6%
FY2025
5-year range
-855.6% / 38.7%
FY2021-FY2025
Trend
-4176.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Opus Genetics, Inc. reports negative total equity of -855.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-855.6% in FY2025 with a 3-year CAGR of -600.5%.
Declined from 38.7% to -855.6% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -600.5pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 4176.0% year-over-year.
- Peak return on equity (roe) was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -855.6% | -4176.0% |
| FY2024 | -20.0% | -151.7% |
| FY2023 | 38.7% | +115.2% |
| FY2022 | -255.1% | - |
| FY2021 | - | - |
| FY2013 | -6.6% | +76.5% |
| FY2011 | -27.9% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026